Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: An analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1879-1886

  Rudenko, Hannah C ^a   Else, Monica ^a   Dearden, Claire ^a   Brito Babapulle, Vasantha ^a   Jones, Chris ^a   Dexter, Tim ^a   Fenwick, Kerry ^a   Mackay, Alan ^a   Ashworth, Alan ^a   Matutes, Estella ^a   Gonzalez, David ^a   Catovsky, Daniel ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ArrayCGH; CLL; FISH; Interstitial deletion; TP53

Indexed keywords

DNA; PROTEIN P53;

BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 18P; CHROMOSOME 20P; CHROMOSOME 2P; CHROMOSOME 6Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME LOSS; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; HUMAN; HUMAN CELL; INTERPHASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRISOMY 12;

AGED; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 20; CLINICAL TRIALS AS TOPIC; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55049115100     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802345902     Document Type: Conference Paper

References (40)

1. Chiorazzi, N., Rai, K. R. and Ferrarini, M. (2005) Chronic lymphocytic leukemia. N Engl J Med, 352, pp. 804-815.
2. Hamblin, T. J. (2005) Chronic lymphocytic leukaemia: Clinical translations of biological features. Curr Top Microbiol Immunol, 294, pp. 165-185.
3. Binet, J. L., Caligaris-Cappio, F., Catovsky, D., Cheson, B., Davis, T. Dighiero, G. et al. (2006) Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood, 107, pp. 859-861.
4. Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N. and Pasternack, B. S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, pp. 219-234.
5. Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H. Goasguen, J. et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, pp. 198-206.
6. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. and Stevenson, F. K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, pp. 1848-1854.
7. Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A. Allen, S. L. et al. (1999) IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, pp. 1840-1847.
8. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D. Rozman, M. et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med, 348, pp. 1764-1775.
9. Hallek, M., Wanders, L., Ostwald, M., Busch, R., Senekowitsch, R. Stern, S. et al. (1996) Serum β(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma, 22, pp. 439-447.
10. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A. Bullinger, L. et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med, 343, pp. 1910-1916.
11. Oscier, D. G., Wade, R., Orchard, J., Davis, Z., Best, G. Morilla, A. et al. (2006) Prognostic factors in the UK LRF CLL4 trial (abstract). Blood, 108, p. 299.
12. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M. J. Bezares, R. F. et al. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet, 370, pp. 230-239.
13. Best, O. G., Gardiner, A. C., Davis, Z. A., Ibbotson, R. E., Majid, A. Dyer, M JS et al. (2007) A subset of CLL patients with TP53 abnormalities and mutated VH genes have stable disease (abstract). Leuk Lymphoma, 48, pp. S80-S81.
14. Greshock, J., Naylor, T. L., Margolin, A., Diskin, S., Cleaver, S. H. Futreal, P. A. et al. (2004) 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res, 14, pp. 179-187.
15. Albertson, D. G. and Pinkel, D. (2003) Genomic microarrays in human genetic disease and cancer. Hum Mol Genet, 12, pp. R145-R152.
16. Natrajan, R., Little, S. E., Sodha, N., Reis-Filho, J. S., Mackay, A. Fenwick, K. et al. (2007) Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol, 211, pp. 52-59.
17. Vousden, K. H. and Lane, D. P. (2007) p53 in health and disease. Nat Rev Mol Cell Biol, 8, pp. 275-283.
18. Bentz, M., Huck, K., du Manoir, S, Joos, S., Werner, C. A. Fischer, K. et al. (1995) Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood, 85, pp. 3610-3618.
19. Gonzalez, D., Martinez, P., Rudenko, H., Brito, V., Gonzalez, M. Hernandez, J. M. et al. (2007) Molecular characterisation of TP53 abnormalities in CLL patients with 17p deletion (abstract). Leuk Lymph, 48, p. S139.
20. Stankiewicz, P., Shaw, C. J., Dapper, J. D., Wakui, K., Shaffer, L. G. Withers, M. et al. (2003) Genome architecture catalyzes nonrecurrent chromosomal rearrangements. Am J Hum Genet, 72, pp. 1101-1116.
21. Fink, S. R., Smoley, S. A., Stockero, K. J., Paternoster, S. F., Thorland, E. C. Van Dyke, D. L. et al. (2006) Loss of TP53 is due to rearrangements involving chromosome region 17p10 ∼ p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet, 167, pp. 177-181.
22. Callet-Bauchu, E., Salles, G., Gazzo, S., Poncet, C., Morel, D. Pages, J. et al. (1999) Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: Frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia, 13, pp. 460-468.
23. Sankar, M., Tanaka, K., Kumaravel, T. S., Arif, M., Shintani, T. Yagi, S. et al. (1998) Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia, 12, pp. 510-516.
24. Hoff, C., Seranski, P., Mollenhauer, J., Korn, B., Detzel, T. Reinhardt, R. et al. (2000) Physical and transcriptional mapping of the 17p13.3 region that is frequently deleted in human cancer. Genomics, 70, pp. 26-33.
25. Goh, K. O. (1985) Chromosomal abnormalities in chronic lymphocytic leukemia. Cancer Genet Cytogenet, 16, pp. 103-107.
26. Pfeifer, D., Pantic, M., Skatulla, I., Rawluk, J., Kreutz, C. Martens, U. M. et al. (2007) Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood, 109, pp. 1202-1210.
27. Fernandez, V., Jares, P., Salaverria, I., Gine, E., Bea, S. Aymerich, M. et al. (2008) Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica, 93, pp. 132-136.
28. Tompkins, V., Hagen, J., Zediak, V. P. and Quelle, D. E. (2006) Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle, 5, pp. 641-646.
29. Lowe, S. W. and Sherr, C. J. (2003) Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev, 13, pp. 77-83.
30. Eymin, B., Leduc, C., Coll, J. L., Brambilla, E. and Gazzeri, S. (2003) p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene, 22, pp. 1822-1835.
31. Perucca, P., Cazzalini, O., Mortusewicz, O., Necchi, D., Savio, M. Nardo, T. et al. (2006) Spatiotemporal dynamics of p21CDKN1A protein recruitment to DNA-damage sites and interaction with proliferating cell nuclear antigen. J Cell Sci, 119, pp. 1517-1527.
32. Haferlach, C., Dicker, F., Schnittger, S., Kern, W. and Haferlach, T. (2007) Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia, 21, pp. 2442-2451.
33. Lehmann, S., Ogawa, S., Raynaud, S. D., Sanada, M., Nannya, Y. Ticchioni, M. et al. (2008) Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer, 112, pp. 1296-1305.
34. Satterwhite, E., Sonoki, T., Willis, T. G., Harder, L., Nowak, R. Arriola, E. L. et al. (2001) The BCL11 gene family: Involvement of BCL11A in lymphoid malignancies. Blood, 98, pp. 3413-3420.
35. Joos, S., Menz, C. K., Wrobel, G., Siebert, R., Gesk, S. Ohl, S. et al. (2002) Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood, 99, pp. 1381-1387.
36. Schwaenen, C., Nessling, M., Wessendorf, S., Salvi, T., Wrobel, G. Radlwimmer, B. et al. (2004) Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA, 101, pp. 1039-1044.
37. Chevallier, P., Penther, D., Avet-Loiseau, H., Robillard, N., Ifrah, N. Mahe, B. et al. (2002) CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol, 116, pp. 142-150.
38. Stilgenbauer, S., Sander, S., Bullinger, L., Benner, A., Leupolt, E. Winkler, D. et al. (2007) Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica, 92, pp. 1242-1245.
39. Andritsos, L. A., Jones, J., Lozanski, G., Lin, T. S., Blum, K. A. Grever, M. R. et al. (2007) Del(17p13.1) in chronic lymphocytic leukemia confers poor prognosis even at low percentage involvement and increases proportionately with increase in clonal involvement (abstract). Blood, 110, p. 2073.
40. Zenz, T., Habe, S., Denzel, T., Winkler, D., Dohner, H. and Stilgenbauer, S. How little is too much? p53 inactivation: From laboratory cutoff to biological basis of chemotherapy resistance. Leukemia